These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 861963)

  • 21. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of 5-azacytidine in solid tumors.
    Weiss AJ; Metter GE; Nealon TF; Keanan JP; Ramirez G; Swaiminathan A; Fletcher WS; Moss SE; Manthei RW
    Cancer Treat Rep; 1977; 61(1):55-8. PubMed ID: 67894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
    Rege VB; Owens AH
    Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
    [No Abstract]   [Full Text] [Related]  

  • 28. Toxicity study of BCNU (NSC-409962) given orally.
    Lessner HE; Vogler WR
    Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
    Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
    Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemotherapy for malignant mesothelioma with adriamycin and continuous infusion of 5-azacytidine.
    Chahinian AP; Holland JF; Mandel EM
    Cancer Treat Rep; 1978 Jul; 62(7):1108-9. PubMed ID: 80270
    [No Abstract]   [Full Text] [Related]  

  • 31. Relationship between alternate-day corticosteroid therapy and behavioral abnormalities.
    Sharfstein SS; Sack DS; Fauci AS
    JAMA; 1982 Dec; 248(22):2987-9. PubMed ID: 7143671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
    Schmoll HJ; Niederle N; Achterrath W
    Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation.
    Misset JL; Mathé G; Tubiana M; Caillou B; de Vassal F; Pouillart P; Gil M; Tentas C; Hayat M; Schwarzenberg L; Jasmin C; Delgado M; Machover D; Ribaud P; Musset M
    Cancer Chemother Pharmacol; 1978; 1(4):197-202. PubMed ID: 373920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas.
    O'Connell MJ; Silverstein MN; Kiely JM; White WL
    Cancer Treat Rep; 1977; 61(1):65-8. PubMed ID: 861963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.